ABVD
chemotherapy regime used in the treatment of Hodgkin's lymphoma
ABVD is a chemotherapy regimen used in the first-line treatment of Hodgkin lymphoma, replacing the older MOPP protocol. It consists of concurrent treatment with the chemotherapy drugs:
Adriamycin (also known as doxorubicin/hydroxydaunorubicin, designated as H in CHOP)
Bleomycin
Vinblastine
Dacarbazine (similar to procarbazine, designated as P in MOPP and in COPP)
Medical uses
As of 2007, ABVD is widely used as the initial chemotherapy treatment for newly diagnosed Hodgkin lymphoma. It has been the most effective and least toxic chemotherapy regimen available for treating early-stage Hodgkin Lymphoma. The other chemotherapy regimens that are widely used in this setting is the Stanford V and BEACOPP regimens.
Administration
One cycle of ABVD chemotherapy is typically given over 4 weeks in two doses, with the first on day 1 and the second dose on day 15. All four of the chemotherapy drugs are given intravenously. ABVD chemotherapy is usually given in the outpatient setting — that is, it does not require hospitalization.
Typical dosages for one 28-day cycle of ABVD are:
Dosages above are given according to the body surface area dosing model.
The number of cycles given depends upon the stage of the disease and how well the patient tolerates chemotherapy. Doses may be delayed because of neutropenia, thrombocytopenia, or other side effects.
“ABVD” enters the record as chemotherapy regime used in the treatment of Hodgkin's lymphoma. Crown Archives preserves that source wording while asking what ABVD, chemotherapy and regime can confirm, complicate or overturn.
Why this record matters
“ABVD” is worth following because a concise public description often conceals a longer documentary argument. Here, ABVD, chemotherapy and regime provides the most credible route into that argument.
Vocabulary and entity names are the principal evidence signals here, because they determine the precision of every later search. The source revision retrieved here is dated May 21, 2026. The linked authority identifier is Q287631. None of the 0 selected statements returned an explicit reference. The first chronological checks are 2007.
A concise general-reference account can conceal disagreements about scope, terminology or the weight assigned to individual sources. The source lead contains qualifying language; that uncertainty should survive quotation, summary and reuse. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.
- Subject orientation
- Search vocabulary
- Locating named sources
The closest primary source, responsible institution and strongest cited specialist reference.
Three-step research path
- Establish the record: confirm the title “ABVD”, its source revision and the description used here.
- Expand the search: follow ABVD primary sources, ABVD archive and ABVD research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “ABVD”?
- Which institution is responsible for the underlying evidence?
- What terminology or title could unlock a more precise catalogue search?
Search terms from this dossier
This entry incorporates text from “ABVD” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.